Current Strategies for Knee Cartilage Repair
Nick Kalson, Panagiotis Gikas, Timothy Briggs
To cite this version:
Nick Kalson, Panagiotis Gikas, Timothy Briggs. Current Strategies for Knee Cartilage Repair. International Journal of Clinical Practice, Wiley, 2010, 64 (10), pp.1444. 10.1111/j.17421241.2010.02420.x. hal-00566327
HAL Id: hal-00566327
https://hal.archives-ouvertes.fr/hal-00566327
Submitted on 16 Feb 2011
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
International Journal of Clinical Practice
rP
Fo
#" $
% $
)%
$
&
*
0,
'
+
,1
. $
rR
(
ee
"
!
+
2 11 +
-
#
. $
$ -
. $
/
#
#
/
/
+2
+2
w
ie
ev
ly
On
International Journal of Clinical Practice
International Journal of Clinical Practice
Page 1 of 26
Current Strategies for Knee Cartilage Repair
Nicholas S. Kalson, Panagiotis D. Gikas*, Timothy W. R. Briggs
Bone Tumour Service, Royal National Orthopaedic Hospital, Brockley Hill,
Fo
Stanmore, Middlesex, UK. HA7 4LP.
rP
* Author for correspondence. Email,
[email protected], Telephone +44
7958342989
ee
Key words: Knee, cartilage, injury, microfracture, autologous chondrocyte
implantation, mosaicplasty
iew
ev
rR
ly
On
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
International Journal of Clinical Practice
Page 2 of 26
International Journal of Clinical Practice
Abstract
Defects in knee articular cartilage can cause pain and disability and present the
clinician with an extremely challenging clinical situation. This article describes the
most up-to-date surgical techniques that aim to repair and/or regenerate
symptomatic focal defects in articular cartilage, which include arthroscopic
debridement, microfracture bone marrow stimulation and autologous osteochondral
allografting, with an emphasis on autologous chondrocyte implantation (ACI). In the
Fo
future, refinement of tissue engineering approaches promises to further improve
outcome for these patients.
iew
ev
rR
ee
rP
ly
On
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
International Journal of Clinical Practice
International Journal of Clinical Practice
Page 3 of 26
Introduction
Knee articular cartilage (AC) defects have long presented a challenge to physicians.
In 1743 the famous English anatomist William Hunter wrote ‘an ulcerated cartilage is
a trouble-some problem… that, once destroyed, it is not recovered’ [1]. Today, more
than 250 years later, cartilage damage is still an issue for physicians and patients and
there is still no universally accepted and successful treatment approach for damaged
AC. However, the result of research into novel surgical therapies developed over the
Fo
last two decades, described in this article, have the potential to consign this
statement to history.
ee
rP
Importance of knee cartilage defects
rR
Articular cartilage lesions are common. In patients undergoing arthroscopic
investigation for knee symptoms the incidence of cartilage defects has been found to
be 61% [2] and 63% [3] and the prevalence of work- or sport-related articular lesions
ev
has been reported at 22% and 50% [4, 5]. Furthermore, in patients with anterior
cruciate laxity the incidence of articular pathology is as high as 54% [6]. Although
iew
more common with age, these injuries are also frequent in patients less than 55
years old [3, 7], in whom a prosthetic joint replacement, with a limited lifespan, is
not recommended. Therefore alternative treatments are required. Focal AC defects
On
are most often traumatic in origin, resulting from a high-load impact or repetitive
shear and torsional loads on the superficial zone of articular cartilage [8]. A small
proportion of lesions are caused by osteochondritis dessicans (less than 5%)[9]. Focal
ly
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
AC defects are separate from osteoarthritis, a chronic degenerative disease, which
has distinct clinical, radiological and arthroscopic findings.
Natural history of knee cartilage defects
International Journal of Clinical Practice
International Journal of Clinical Practice
Hyaline AC is predominantly composed of a unique extra-cellular matrix (ECM),
formed from embryonic mesenchyme in a complex and incompletely understood
developmental process [10]. The two principal components of AC are proteoglycans,
negatively charged glyocsaminoglyan chains that swell and hydrate AC, and collagen
type II, a fibrillar collagen that traps the proteoglycans and provides tensile strength.
This ECM is specialised to cope with its singular biomechanical environment; to
regain a functional joint, cartilage defects would ideally be replaced by tissue of this
Fo
precise composition.
Injury to some musculoskeletal tissues, such as bone, result in recapitulation of
rP
embryonic development processes and regeneration of fully functional tissue
identical to the pre-injured tissue. However, there are several barriers to intrinsic
ee
articular cartilage repair: 1) It is avascular, meaning that the nutrients required for
energetic repair processes and the removal of metabolic waste products are limited
rR
by diffusion to/from surrounding tissues. 2) It is relatively acellular, therefore few
cells are available to effect repair. These obstacles conspire to limit repair of defects
ev
to a fibro-cartilaginous substitute tissue with different molecular composition (more
type I collagen, less proteoglycan) and biomechanical behaviour (less proteoglycan
iew
and collagen type II, more collagen type I), compared to the original hyaline tissue
[11, 12].
Despite this clear pathological response to injury the natural history of untreated AC
On
lesions is not fully understood [13]. Shelbourne et al. (2003) reported a series of
patients identified with AC defects discovered at the time of arthroscopic cruciate
ly
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Page 4 of 26
ligament reconstruction. Patients left with untreated AC lesions had similar
subjective patient scores at an average follow up of nine years than control subjects
with no AC defects. Interestingly, the authors also noted that a number of patients
with significant AC defects have no/mild clinical symptoms [5]. In another treatment
intervention trial patients treated only with debridement and no surgical repair
procedure showed spontaneous improvement [14]. Therefore, although some
lesions will be asymptomatic, AC defects have the potential to manifest as continued
joint pain, impaired movement and functional disability, that will need treating in a
International Journal of Clinical Practice
International Journal of Clinical Practice
Page 5 of 26
carefully selected group of patients. Additionally, it is known that AC defects
increase the risk of osteoarthritis, which may require knee replacement [15].
Therefore, it is desirable to intervene not only to reduce current morbidity but also
in order to reduce the likelihood of future joint disorder.
Patient selection and indication for surgery
Fo
A wide-range of non-specific symptoms may lead clinicians to consider that an AC
defect is the source of a patient’s pain, including locking, pain at rest, swelling, pain
rP
with activity, instability and retropatellar crepitus [16, 17]. Approximately two thirds
of patients with chondral defects have associated ligamentous or meniscal pathology
ee
and AC damage has been reported in association with 23% of ACL injuries and 54%
of knees with chronic anterior cruciate ligament laxity or instability [6]. Focal AC
rR
defects are distinct from osteoarthritis, which often involves more widespread
cartilage damage and prominent subchondral bony changes, is predominantly a
ev
disease of old age, and has a chronic, gradually worsening course.
iew
Cartilage lesions are graded I-IV according the International Cartilage Repair Society
scale [18]. Grade I lesions are nearly normal with only superficial fissures, grade II
lesions extend less than 50% of cartilage depth, grade III are severely abnormal
lesions extending more than 50% of cartilage depth, but not into the subchondral
On
bone, and grade IV lesions include the subchondral bone.
ly
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Clinical examination is supported by arthroscopic assessment, the gold standard
investigation for chondral defects, which allows direct visualisation of the chondral
surface. In addition, magnetic resonance imaging (MRI) has a high sensitivity and
specificity to detect chondral defects (greater than 95% for grade III lesions [19]).
High resolution MRI can provide sufficient information for operative planning, and
might in future obviate the need for diagnostic arthroscopy. Most importantly, the
commonly occurring asymptomatic AC defect makes it essential that care is taken
during clinical examination and investigations to determine that findings correlate
International Journal of Clinical Practice
Page 6 of 26
International Journal of Clinical Practice
with clinical symptoms, therefore ensuring that treatment is not misdirected [5].
Patient selection and indications for surgery vary according to the treatment type,
and are considered further below.
Current treatment options
Fo
Orthopaedic surgeons have developed a wide arsenal of treatment options for
treating focal knee AC defects [20]. Those most commonly employed today include,
but are not limited to: 1) arthroscopic debridement, in which loose cartilage is
rP
trimmed, 2) microfracture, in which bone marrow based repair is stimulated, 3)
autologous osteochondral grafting, in which bone-cartilage plugs are harvested from
ee
non-weight bearing joint sites and implanted directly into the defect, and 4)
autologous chondrocyte implantation, a two-stage procedure involving harvest of
rR
chondrocytes, growth in vitro, then re-implantation.
ev
Which treatment is chosen depends on several factors, including size of lesion,
availability of particular treatments and the age and requirements of the patient.
iew
Small lesions may be conservatively managed with arthroscopic debridement and
careful monitoring [14, 21], whereas more extensive lesions require greater
intervention. The first choice treatment for lesions less than 2.5 cm2 is bone marrow
stimulation by microfracture [8, 22-24]. Larger lesions may be treated by
On
mosaicplasty[17], this technique is limited by the availability of donor tissue, or by
autologous chondrocyte transplantation, which is becoming more widely available
ly
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
[8]. Other treatments, such as abrasion chondroplasty and the use of carbon fibre
pads, are either less widely practised, or have been superseded, and are therefore
not discussed.
Arthroscopic debridement
International Journal of Clinical Practice
Page 7 of 26
Small defects in which there are loose, overhanging flaps of cartilage may initially be
treated by arthroscopic debridement [14, 21]. These lesions often present with
locking. However, larger, more complex defects, perhaps with no obvious loose
body, require more complex procedures, which either stimulate repair tissue
(microfracture) or replace damaged cartilage (osteochondral transplantation or
autologous chondrocyte implantation).
Fo
Bone marrow stimulation by microfracture
Bone marrow stimulation by microfracture is widely considered the first choice
rP
treatment for small lesions (less than 2.5 cm2) [8, 22-24] (Figure 3). Bone marrow
stimulation techniques aim to induce bleeding for the subchondral bone followed by
ee
the formation of a fibrin clot, migration and recruitment of bone marrow derived
stem cells and the formation of a fibrocartilaginous repair tissue that covers full-
rR
thickness chondral lesions. Bony drilling into the defect, first described by Pridie in
1959 [25], was prevalent until the advent of microfracture in the 1990s [26]. Pridie
ev
drilling uses a hand-driven or motorised drill to penetrate the subchondral plate. This
is thought to cause heat-related tissue damage, whereas microfracture uses a
iew
gentler arthroscopic awl, which does not generate significant heat [27, 28].
Microfracture is now more popular than other bone marrow stimulation techniques
(drilling and arthroscopic abrasion arthroplasty [29]).
On
Microfracture has demonstrated good or excellent results in 60-80% of patients [27,
30, 31]. There is some evidence that MF works best in patients under 40 years old
ly
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
International Journal of Clinical Practice
that might have intrinsically superior healing responses to those in older patients
[32].
It benefits from the low-morbidity of an arthroscopic procedure with a
relatively quick recovery period and low complication rate [30, 33].
Treatable lesions are 1-2.5 cm2 large, and well shouldered with protected edges [8].
Microfracture involves debridement of unstable cartilage to bone level to form a
stable rim of healthy cartilage around the defect. Specially designed awls are then
used to make multiple holes 2-4 mm deep and 3-4 mm apart in the subchondral
International Journal of Clinical Practice
International Journal of Clinical Practice
bone [34]. Rehabilitation includes continuous passive motion and partial weight
bearing for 6-8 weeks. Interestingly, non-human primate models of microfracture
show repair tissue to be immature after six weeks, suggesting a longer rehabilitation
period might be necessary [35].
The procedure may be less-well suited to the patello-femoral joint or the tibia, which
in one study showed deterioration after 18 months following microfracture [24], or
Fo
to lesions larger than 4 cm2, which have been reported to fair better after treatment
with autologous chondrocyte transplantation [22, 23]. Complications include
degenerative changes in the subchondral area, such as cysts, osseous overgrowth
rP
and intra-lesional osteophytes in approximately 33% of cases [24, 27]. The
significance of these findings has not been proven, but changes to the subchondral
ee
plate likely underlie failed MF treatment [33].
rR
Microfracture is not a curative treatment, but it can provide relief for a number of
years. However, doubts remain over the durability of the repair tissue produced,
ev
which is fibrocartilagenous and has inferior biomechanical properties compared to
hyaline tissue. Mithoefer et al. (2009) conducted a systematic review examining the
iew
clinical efficacy of MF for knee AD defects. They identified six randomised control
trails, which all showed improved knee function during the first 24 months postoperation, but the longevity of the initial improvement was not consistent between
studies [36]. Furthermore, a recent report of microfracture used to treat
On
professional athletes concluded that ‘from a strict scientific stand point an untreated
control group would be valuable to demonstrate that microfracture does not just
ly
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Page 8 of 26
mirror the natural course of healing’ [37]. There are currently no published studies
comparing MF (or any other intervention) to an untreated control group. This should
be an important future research goal.
Autologous osteochondral grafting / mosaicplasty
Autologous osteochondral allografting, also known as mosaicplasty, most commonly
involves transplantation of small (less than 1cm2) cylindrical cartilage plugs
International Journal of Clinical Practice
Page 9 of 26
harvested from non-weight bearing areas such as the lateral femoral condyle or the
trochlea, directly into the defect in a one-stage procedure [17] (Figure 2). The use of
different size plugs allows defect filling of more than 90%, and the graft needs to be
perpendicular and flush to the surface to prevent catching with knee motion [17].
This technique has the advantage of directly implanting hyaline cartilage onto the
defect. The procedure may be done open or arthroscopically, and is not
recommended in individuals over 50 years old [17]. Good to excellent results have
Fo
been reported in 85-95% of treated defects of the femoral condyles, tibial surfaces
and patellar/trochlear lesions [38-43].
rP
It is important to note that repair using autologous tissue technique is most suited to
small (less than 4 cm2) lesions, being limited by the availability of donor tissue and by
ee
potential donor-site morbidity [17, 44]. Larger defects may be filled with allogenous
cartilage tissue from a cadaveric donor, although this risks immunologic rejection
rR
and disease transmission from donor to recipient. Therefore osteochondral
allografts are generally reserved for uncontained (not well-defined) lesions greater
ev
than 4 cm2 where there is significant osseous damage [8].
iew
Autologous chondrocyte implantation
By 2003 more than 15,000 patients have undergone ACI worldwide [45] and it is now
widely considered the frontline treatment for defects larger than 2 cm2 [8] (Figure
On
4). The procedure is recommended for ICRS grade III/IV lesions of the femoral
condyle or trochlear region, but more recently has been used with success for
ly
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
International Journal of Clinical Practice
patellar lesions. The optimum candidate is a highly motivated patient, less than 5055 years old, with a high functional demand and high potential for compliance with
the long-term rehabilitation required (reviewed in [8]).
Indications
The size of a lesion best suited to ACI is still debated. Conventional thinking is that
lesions less than 2-2.5 cm2 may be treated initially with microfracture, and that ACI
may be used in patients that continue to have pain after microfracture. However,
International Journal of Clinical Practice
Page 10 of 26
International Journal of Clinical Practice
although microfracture was considered a ‘non bridge-burning procedure’ [33], a
recent study suggests that previous microfracture reduces the chances of successful
ACI by 30% [33]. Bone involvement is not a contraindication, but when bone
involvement is deeper than 6 – 8 mm autologous bone grafting should be
undertaken (Petersen 2003). Reciprocal (kissing) lesions are generally a
contraindication.
Fo
Pre-operative assessment
In pre-operative planning weight loss is central, and a BMI less than 30 kg/m2 is
recommended. Weight loss has been associated with improved activities of daily
rP
living scores and SF-36 Physical Component Summary Scores following cartilage
repair procedures [27]. Clinical assessment should include knee alignment and
ee
associated injuries. Malalignment should be corrected by osteotomy, and knee
ligaments reconstructed. Meniscal lesions require repair or resection at initial
rR
arthroscopy. Radiographic assessment includes postero-anterior weight bearing
views to assess for medial/lateral compartment narrowing, bilateral Merchant views
ev
to assess patellar facet wear, subluxation and tilt, and bilateral long-limb standing
radiographs to examine the leg axis and potential sites of increased load to the
iew
repair site. Magnetic resonance imaging has a high sensitivity and specificity (over
90%) for detecting AC defects, but only lesions that correlate with clinical symptoms
should be treated.
Surgical technique
On
Two separate procedures are required for ACI. First, arthroscopic assessment is
ly
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
performed after physical examination and radiographic studies. If areas of ICRS
grade III/IV are found, the lesions are measured. If the reciprocal surface is not
severely damaged and the patient is an appropriate candidate for chondrocyte
implantation a biopsy is taken. Harvest is from a non-weight bearing area of articular
cartilage, such as the medial edge of the trochlear groove. Approximately 200-300
mg of tissue are taken, which corresponds to approximately 300,000 cells. It is
important to remove tissue from a healthy area in order that ‘normal’ chondrocytes
are collected. Chondrocytes are cultured for 4-6 weeks in a laboratory compliant
International Journal of Clinical Practice
International Journal of Clinical Practice
Page 11 of 26
with Good Manufacturing Practice guidelines. It is important that chondrocytes are
not cultured longer than this, or phenotypic changes emerge. Either a chondrocyte
suspension, or chondrocytes seeded on a collagen-based scaffold (matrix assisted
autologous chondrocyte implantation – MACI) is then implanted in a second
procedure. The defect is prepared by debriding the edges to normal articular
cartilage. Damage to the underlying chondral bone is avoided to prevent bleeding
into the defect. In ACI, a periosteal graft, which may be harvested from the proximal
Fo
tibia, is used to cover the implanted cells [46], or chondrocytes can be implanted
beneath a collagen membrane (ACI-C). In the MACI technique, cells are seeded on a
collagen type I/III scaffold at a precise concentration (1 million cells per cm2). The
rP
membrane is placed directly into the defect and secured with fibrin glue, eliminating
the need for suturing to surrounding cartilage and use of a cover, which can damage
ee
surrounding healthy cartilage.
Rehabilitation
rR
Rehabilitation protocols vary widely, but always involve a long and cautious process,
ev
requiring high motivation and patient compliance. When planning rehabilitation it is
important to remember that a biological healing process is occurring, which involves
iew
cell proliferation (0-6 weeks), matrix production (first 6 months), and matrix
remodeling (6 months onward). Most protocols require reduced weight bearing for
10 weeks, aiming to avoid impact loading and twisting or shearing forces which
might damage the repair tissue. One protocol uses a plaster of Paris for week one,
On
then toe-touch weight bearing with flexion-extension exercises at weeks two-six
[47]. From six weeks partial weight bearing is used, and from ten weeks full weight
ly
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
bearing is allowed. Other regimes use passive movement from day one onwards,
which aims to stimulate implanted cells via mechanical signals as early as possible
[48]. It ought to be noted that the ideal mobilization protocol aims to optimize the
repair process, and it is tailored to the individual case. Well-contained lesions are
protected by surrounding cartilage and may begin weight bearing at 4 weeks,
whereas large poorly contained lesions should not bear weight fully until 8-12 weeks
post-surgery [8].
International Journal of Clinical Practice
International Journal of Clinical Practice
Post-operative assessment
Arthroscopy remains the gold standard for post-operative evaluation, often carried
out at one year post-operation, and allows visualisation of the repair and biopsy for
histological assessment. Probe indentation stiffness can also be measured, and has
demonstrated up to 80% stiffness compared with native articular cartilage [49].
Gikas et al. (2009) demonstrated progressive development from fibrocartilage to
hyaline cartilage with increasing time from operation in patients having undergone
Fo
ACI/MACI. The appearances of the repair tissue can also be investigated with MRI
[50]. In one series ACI provided better defect filling than microfracture [51]. More
sophisticated MRI techniques use intravenously administered gadolinium, which can
rP
penetrate cartilage, and T1 imaging can estimate glycosaminoglyan content, and T2
mapping allows evaluation of collagen content (for review see [52]).
rR
Clinical results of ACI
ee
Clinical results for ACI have been encouraging. Numerous case-series report positive
effectiveness of ACI for treatment of knee AC defects, with follow-up now available
ev
more than 10 years post-procedure [53-56]. Furthermore, there are randomised
trials (RCT) comparing ACI to microfracture [20, 23, 57] and to mosaicplasty [58], and
iew
these RCTs have been reviewed in an attempt to determine an optimum treatment
for focal AC defects.
A Cochrane Collaboration meta-analysis identified four randomised control trials
On
comparing ACI with microfracture or mosaicplasty that met their eligibility criteria
[23, 58-61]. One of these trials reported superior outcome for ACI versus
ly
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Page 12 of 26
mosaicplasty [58], whilst the other trials did not find a superior treatment. In one
study one year after treatment ACI was associated with a tissue regenerate that was
superior to that of microfracture [23]. Overall, they could not find evidence to
support ACI over microfracture or mosaicplasty, and concluded that further
randomised trials are required.
Since publication of the Cochrane review (2006) [61], further RCTs have been
published. Knutsen et al. (2007) reported no difference in clinical or radiographic
International Journal of Clinical Practice
International Journal of Clinical Practice
Page 13 of 26
outcome measures at 5-year follow up of patients treated with either microfracture
or ACI [20]. Saris et al. (2008) report similar short-term clinical outcome was for ACI
and microfracture groups [62]. Similarly, Van Assche et al. (2008) reported on 67
patients randomised to microfracture or ACI. Follow-up at two years did not show
differences in functional outcome [63].
Recently, Magnussen et al. (2008) reviewed five randomised control trials comparing
Fo
ACI/MACI, osteochondral autograft transfer and microfracture. All treatments
improved clinical outcome measures compared to pre-operative assessment, but no
technique consistently had superior results, and no study used non-operative control
rP
groups [64]. The authors’ recommendation is that a large prospective trial be
conducted and that non-operated controls be included.
ee
These trials are consistent in reporting clinical improvement following ACI.
rR
Furthermore, economic analysis has demonstrated cost effectiveness of ACI [65].
There is emerging evidence that that the repair tissue produced in ACI is more
ev
hyaline-like and more durable than that following microfracture. [20, 62]. However,
there is currently no firm evidence that ACI provides improved patient outcomes
iew
compared to either microfracture or mosaicplasty. Furthermore, the quality of trial
methodology investigating knee AC defects could be improved by adequately
describing randomisation procedures, including untreated control groups, use of
validated outcome measures and the use of an independent investigator or outcome
assessment [61, 66].
ly
On
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Matrix-assisted/induced autologous chondrocyte implantation
Autologous chondrocyte implantation is considered to be the first widely available
and commercially successful cell-based therapeutic intervention. Undoubtedly, in
the future more cellular therapies will become available to treat a wide variety of
disorders. The pioneering position of ACI at the forefront of medical technology has
understandably led to close scrutiny from medical regulatory authorities. Wood et al.
(2006) reported that the rate of adverse reactions in patients treated with Carticel,
an autologous chondrocyte implant system, was 3.8% (497/7500). Adverse reactions
International Journal of Clinical Practice
International Journal of Clinical Practice
included graft failure (25%), delamination (22%) and tissue hypertrophy (18%) [67]
and most often occurs within 6 months after surgery in approximately 25% cases and
can require surgery [54].
It is thought that tissue hypertrophy is related to the use of a periosteal graft to
cover the implanted chondrocytes, which in addition is technically difficult to harvest
and can cause joint stiffness and arthrofibrosis. The technical advantages of scaffold-
Fo
based techniques (e.g. MACI), which remove the need for an arthrotomy and the risk
of perosteal hypertrophy, have led to some surgeons preferring scaffold techniques
[54]. Therefore, there has been evolution towards implants in which cells are seeded
rP
in a 3D matrix that does not require periosteal cover. Since the late 1990s, when the
European Drug Agency licensed the use of collagen and hyaluronan based scaffolds
ee
for implantation with cultured autologous chondrocytes, several different matrix
based implants have been devised, including Matrix induced autologous
rR
chondrocyte implantation (MACI, Verigen Transplantation Service, Copenhagen,
Denmark), Hyalograft C (Fidia Advanced Biopolymers Laboratories, Padova, Italy),
ev
and CaReS (Ars Arthro, Esslingen, Germany). Mid-long term follow-up is now
becoming available [68], and suggests that MACI gives similar or slightly improved
iew
clinical outcome compared to ACI [47] or microfracture [56]. Biopsy results have also
been encouraging, showing the production of hyaline cartilage [47, 50].
Nevertheless, randomised trials are required to investigate these new procedures
[69].
On
Histological analysis of repair tissue following ACI/MACI reveals that approximately
ly
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Page 14 of 26
50% of patients have hyaline-like or mixed hyaline and fibrocartilage tissue [20, 50].
Although this is certainly improved compared to microfracture [62], why some
chondrocyte implants produce hyaline tissue and others fibro cartilaginous tissue is
not known. This may be due to specific patient, cell-culture or knee injury factors,
and investigation into predicting which patients respond best will be important in
the future. Saris et al. (2008) have begun to investigate manipulation of histological
outcome by characterising and selecting chondrocytes for implantation by gene
expression profile analysis for a number of cartilage marker genes, such as collagen
International Journal of Clinical Practice
Page 15 of 26
type II. They found that superior structural tissue was formed in the ACI group,
which used characterised chondrocytes, compared with microfracture. This is a
promising approach, but further study comparing un-characterised cultured
chondrocytes is required to determine whether cell-selection results in improved
histological outcome [62].
Fo
Future perspectives
Treatment for articular cartilage lesions has pioneered tissue-engineering
rP
techniques, illuminating a path that other therapeutic interventions will undoubtedly
tread. Improvement in clinical outcome has been demonstrated following ACI
ee
treatment, and there are clear routes forward which involve the development of
matrix-based
implants. Currently
minimally invasive
rR
procedures such
as
microfracture are probably best for small defects (less than 2.5 cm2), and ACI for
larger lesions. However, it has been said that no treatment has demonstrated long-
ev
term efficacy [16, 67]. The evidence for ACI providing superior outcomes compared
with treatment by microfracture bone-marrow stimulation is not yet well established
iew
[61, 66] and improvement in the quality of randomised control trials that are
undertaken is required [61, 66].
Chondrocyte implantation holds great promise for future development. The
On
refinement of tissue engineering techniques will include evaluation of different cellscaffold combinations, genetic manipulation of implanted cells, and use of
ly
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
International Journal of Clinical Practice
alternative cell sources such as mesenchymal stem cells. In the future, therapies
might incorporate mechanical stimulation of the tissue ex vivo prior to implantation
(NeoCart), the use of allogenic chondrocyte transplantation (DeNovo ET), use
hydrogel or hyaluronic acid-based scaffolds [70]. There is also a push to develop
single-stage arthroscopic cell-based treatments that use allogenous cells, or
autologous cells of non-cartilage origin (e.g. mesenchymal stem cells) cultured and
differentiated in vitro prior to implantation. Although none of these procedures yet
International Journal of Clinical Practice
Page 16 of 26
International Journal of Clinical Practice
have regulatory approval, the scope for future development of chondrocyte
implantation techniques will, hopefully, result in superior treatments.
Key points
Articular cartilage defects are a common injury, particularly in the young and active
They still present a challenging problem with no universally accepted treatment
Fo
Whether to treat must be directed primarily by clinical information, not solely by the
presence of a lesion
rP
Microfracture is a successful temporary repair procedure, recommended for small
lesions, which produces fibrous tissue and can provide relief for several years
ee
Autologous chondrocyte implantation offers the possibility of regeneration with a
rR
hyaline tissue, and is the recommended front-line treatment for larger defects
Future research will refine tissue engineering techniques to improve outcome with
ev
cell-scaffold treatments
iew
Review criteria
Articles published in English were identified by searching PubMed in December 2009
On
using the following search terms: ‘cartilage and repair’, ‘cartilage and regeneration’,
‘cartilage and articular chondrocyte implantation’, ‘cartilage and osteochondral
autograft’,
‘cartilage
and
microfracture’,
and
ly
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
‘cartilage
transplantation’.
International Journal of Clinical Practice
and
periosteal
Page 17 of 26
Figure Legend
Figure 1. Schematic of a focal knee cartilage defect. (A) A fibrillated cartilage lesion.
(B) Debridement of the defect to healthy cartilage with smooth vertical borders.
Reproduced with permission from [71].
Figure 2. Arthrotomy mosaicplasty. (A) Miniarthrotomy mosaicplasty on the medial
Fo
femoral condyle for the treatment of a chondral defect. Three osteochondral plugs
can be seen implanted in the defect. (B) Mosaicplasty on the medial talar dome to
rP
treat an osteochondritis dessicans defect. Images kindly provided by Laszlo Hangody.
ee
Figure 3. Bone marrow stimulation by microfracture. (A) Small holes 3-4 mm apart
are created in the bone of the defect. Bleeding is induced, which results in healing by
rR
production of fibrocartilagenous tissue. (B) Femoral condyle defect that has been
filled with newly formed fibrocartilagenous tissue. Reproduced with permission from
Lutzner et al. (2009) [72].
iew
ev
Figure 4. Autologous chondrocyte implantation. (B) A focal cartilage defect that has
been debrided to healthy cartilage. (B) Autologous cultured chondrocytes have been
On
implanted into the defect, over which a periosteal flap will be sutured. Reproduced
with permission from Gikas et al. (2009) [47].
ly
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
International Journal of Clinical Practice
International Journal of Clinical Practice
Page 18 of 26
International Journal of Clinical Practice
References
1.
2.
3.
9.
12.
13.
ly
11.
On
10.
iew
8.
ev
7.
rR
6.
ee
5.
rP
4.
Hunter W. On the structure and diseases of articulating cartilage. Phil Trans
Royal Soc. 1743;42B:514-21.
Hjelle K, Solheim E, Strand T et al. Articular cartilage defects in 1,000 knee
arthroscopies. Arthroscopy : the journal of arthroscopic & related surgery :
official publication of the Arthroscopy Association of North America and the
International Arthroscopy Association. 2002 Sep 1;18(7):730-4.
Curl WW, Krome J, Gordon ES et al. Cartilage injuries: a review of 31,516 knee
arthroscopies. Arthroscopy : the journal of arthroscopic & related surgery :
official publication of the Arthroscopy Association of North America and the
International Arthroscopy Association. 1997 Aug 1;13(4):456-60.
Piasecki DP, Spindler KP, Warren TA et al. Intraarticular injuries associated
with anterior cruciate ligament tear: findings at ligament reconstruction in
high school and recreational athletes. An analysis of sex-based differences.
Am J Sports Med. 2003 Jul-Aug;31(4):601-5.
Shelbourne KD, Jari S, Gray T. Outcome of untreated traumatic articular
cartilage defects of the knee: a natural history study. The Journal of bone and
joint surgery American volume. 2003 Jan 1;85-A Suppl 2:8-16.
Indelicato PA, Bittar ES. A perspective of lesions associated with ACL
insufficiency of the knee. A review of 100 cases. Clin Orthop Relat Res. 1985
Sep 1(198):77-80.
Noyes FR, Bassett RW, Grood ES, Butler DL. Arthroscopy in acute traumatic
hemarthrosis of the knee. Incidence of anterior cruciate tears and other
injuries. The Journal of bone and joint surgery American volume. 1980 Jul
1;62(5):687-95, 757.
Jones DG, Peterson L. Autologous chondrocyte implantation. The Journal of
bone and joint surgery American volume. 2006 Nov 1;88(11):2502-20.
Widuchowski W, Widuchowski J, Trzaska T. Articular cartilage defects: study
of 25,124 knee arthroscopies. Knee. 2007 Jun 1;14(3):177-82.
Morrison EH, Ferguson MW, Bayliss MT, Archer CW. The development of
articular cartilage: I. The spatial and temporal patterns of collagen types. J
Anat. 1996 Aug;189 ( Pt 1):9-22.
Furukawa T, Eyre DR, Koide S, Glimcher MJ. Biochemical studies on repair
cartilage resurfacing experimental defects in the rabbit knee. J Bone Joint
Surg Am. 1980 Jan;62(1):79-89.
Cheung HS, Lynch KL, Johnson RP, Brewer BJ. In vitro synthesis of tissuespecific type II collagen by healing cartilage. I. Short-term repair of cartilage
by mature rabbits. Arthritis Rheum. 1980 Feb;23(2):211-9.
Widuchowski W, Lukasik P, Kwiatkowski G et al. Isolated full thickness
chondral injuries. Prevalance and outcome of treatment. A retrospective
study of 5233 knee arthroscopies. Acta chirurgiae orthopaedicae et
traumatologiae Cechoslovaca. 2008 Oct 1;75(5):382-6.
Fo
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
International Journal of Clinical Practice
Page 19 of 26
14.
15.
16.
17.
18.
25.
27.
28.
29.
ly
26.
On
24.
iew
23.
ev
22.
rR
21.
ee
20.
rP
19.
Dozin B, Malpeli M, Cancedda R et al. Comparative evaluation of autologous
chondrocyte implantation and mosaicplasty: a multicentered randomized
clinical trial. Clin J Sport Med. 2005 Jul;15(4):220-6.
Gelber AC, Hochberg MC, Mead LA et al. Joint injury in young adults and risk
for subsequent knee and hip osteoarthritis. Ann Intern Med. 2000 Sep
5;133(5):321-8.
Ochi M, Adachi N, Nobuto H et al. Articular cartilage repair using tissue
engineering technique--novel approach with minimally invasive procedure.
Artif Organs. 2004 Jan;28(1):28-32.
Hangody L, Rathonyi GK, Duska Z et al. Autologous osteochondral
mosaicplasty. Surgical technique. J Bone Joint Surg Am. 2004 Mar;86-A Suppl
1:65-72.
International Cartilage Repair Society. Cartilage Injury Evaluation Package.
2000. Accessed 01 Jan 2010. Available from:
www.cartilage.org/_files/contentmanagement/ICRS_evaluation.pdf
Palosaari K, Ojala R, Blanco-Sequeiros R, Tervonen O. Fat suppression
gradient-echo magnetic resonance imaging of experimental articular cartilage
lesions: comparison between phase-contrast method at 0.23T and chemical
shift selective method at 1.5T. J Magn Reson Imaging. 2003 Aug;18(2):22531.
Knutsen G, Drogset JO, Engebretsen L et al. A randomized trial comparing
autologous chondrocyte implantation with microfracture. Findings at five
years. J Bone Joint Surg Am. 2007 Oct;89(10):2105-12.
Levy AS, Lohnes J, Sculley S et al. Chondral delamination of the knee in soccer
players. Am J Sports Med. 1996 Sep-Oct;24(5):634-9.
Bekkers JE, Inklaar M, Saris DB. Treatment selection in articular cartilage
lesions of the knee: a systematic review. Am J Sports Med. 2009 Nov;37 Suppl
1:148S-55S.
Knutsen G, Engebretsen L, Ludvigsen TC et al. Autologous chondrocyte
implantation compared with microfracture in the knee. A randomized trial. J
Bone Joint Surg Am. 2004 Mar;86-A(3):455-64.
Kreuz PC, Steinwachs MR, Erggelet C et al. Results after microfracture of fullthickness chondral defects in different compartments in the knee.
Osteoarthritis Cartilage. 2006 Nov;14(11):1119-25.
Pridie K. A method of resurfacing osteoarthritic knee joints. J Bone Joint Surg
Am. 1958;41:2.
Blevins FT, Steadman JR, Rodrigo JJ, Silliman J. Treatment of articular
cartilage defects in athletes: an analysis of functional outcome and lesion
appearance. Orthopedics. 1998 Jul;21(7):761-7; discussion 7-8.
Mithoefer K, Williams RJ, 3rd, Warren RF et al. The microfracture technique
for the treatment of articular cartilage lesions in the knee. A prospective
cohort study. J Bone Joint Surg Am. 2005 Sep;87(9):1911-20.
Gill TJ, Asnis PD, Berkson EM. The treatment of articular cartilage defects
using the microfracture technique. J Orthop Sports Phys Ther. 2006
Oct;36(10):728-38.
Johnson LL. Arthroscopic abrasion arthroplasty: a review. Clin Orthop Relat
Res. 2001 Oct(391 Suppl):S306-17.
Fo
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
International Journal of Clinical Practice
International Journal of Clinical Practice
Page 20 of 26
International Journal of Clinical Practice
30.
31.
32.
33.
39.
42.
43.
ly
41.
On
40.
iew
38.
ev
37.
rR
36.
ee
35.
rP
34.
Steadman JR, Briggs KK, Rodrigo JJ et al. Outcomes of microfracture for
traumatic chondral defects of the knee: average 11-year follow-up.
Arthroscopy : the journal of arthroscopic & related surgery : official
publication of the Arthroscopy Association of North America and the
International Arthroscopy Association. 2003 Jan 1;19(5):477-84.
Asik M, Ciftci F, Sen C et al. The microfracture technique for the treatment of
full-thickness articular cartilage lesions of the knee: midterm results.
Arthroscopy. 2008 Nov;24(11):1214-20.
Kreuz PC, Erggelet C, Steinwachs MR et al. Is microfracture of chondral
defects in the knee associated with different results in patients aged 40 years
or younger? Arthroscopy. 2006 Nov;22(11):1180-6.
Minas T, Gomoll AH, Rosenberger R et al. Increased failure rate of autologous
chondrocyte implantation after previous treatment with marrow stimulation
techniques. Am J Sports Med. 2009 May;37(5):902-8.
Steadman JR, Rodkey WG, Rodrigo JJ. Microfracture: surgical technique and
rehabilitation to treat chondral defects. Clin Orthop Relat Res. 2001 Oct(391
Suppl):S362-9.
Gill TJ, McCulloch PC, Glasson SS et al. Chondral defect repair after the
microfracture procedure: a nonhuman primate model. Am J Sports Med.
2005 May;33(5):680-5.
Mithoefer K, McAdams T, Williams RJ et al. Clinical efficacy of the
microfracture technique for articular cartilage repair in the knee: an
evidence-based systematic analysis. Am J Sports Med. 2009 Oct;37(10):205363.
Riyami M, Rolf C. Evaluation of microfracture of traumatic chondral injuries
to the knee in professional football and rugby players. J Orthop Surg Res.
2009;4:13.
Ghazavi MT, Pritzker KP, Davis AM, Gross AE. Fresh osteochondral allografts
for post-traumatic osteochondral defects of the knee. J Bone Joint Surg Br.
1997 Nov;79(6):1008-13.
Szerb I, Hangody L, Duska Z, Kaposi NP. Mosaicplasty: long-term follow-up.
Bull Hosp Jt Dis. 2005;63(1-2):54-62.
Emmerson BC, Gortz S, Jamali AA et al. Fresh osteochondral allografting in
the treatment of osteochondritis dissecans of the femoral condyle. Am J
Sports Med. 2007 Jun;35(6):907-14.
Marcacci M, Kon E, Delcogliano M et al. Arthroscopic autologous
osteochondral grafting for cartilage defects of the knee: prospective study
results at a minimum 7-year follow-up. Am J Sports Med. 2007
Dec;35(12):2014-21.
Tetta C, Busacca M, Moio A et al. Knee Osteochondral Autologous
Transplantation: Long-term MR findings and clinical correlations. Eur J Radiol.
2009 Jun 11.
Solheim E, Hegna J, Oyen J et al. Osteochondral autografting (mosaicplasty) in
articular cartilage defects in the knee: results at 5 to 9 years. Knee. 2010
Jan;17(1):84-7.
Fo
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
International Journal of Clinical Practice
Page 21 of 26
44.
45.
46.
47.
48.
50.
55.
58.
59.
ly
57.
On
56.
iew
54.
ev
53.
rR
52.
ee
51.
rP
49.
Choi YS, Potter HG, Chun TJ. MR imaging of cartilage repair in the knee and
ankle. Radiographics : a review publication of the Radiological Society of
North America, Inc. 2008 Jan 1;28(4):1043-59.
Minas T. Autologous chondrocyte implantation in the arthritic knee.
Orthopedics. 2003 Sep;26(9):945-7.
Brittberg M, Lindahl A, Nilsson A et al. Treatment of deep cartilage defects in
the knee with autologous chondrocyte transplantation. N Engl J Med. 1994
Oct 6;331(14):889-95.
Gikas PD, Bayliss L, Bentley G, Briggs TWR. An overview of autologous
chondrocyte implantation. The Journal of bone and joint surgery British
volume. 2009 Aug 1;91(8):997-1006.
ACTIVE Trial. Accessed 03 Jan 2010. Available from:
http://www.activetrial.org.uk/ACTIVESite/Active%20protocol3.6_Apr08.pdf
Vasara AI, Nieminen MT, Jurvelin JS et al. Indentation stiffness of repair tissue
after autologous chondrocyte transplantation. Clin Orthop Relat Res. 2005
Apr(433):233-42.
Gikas PD, Morris T, Carrington R et al. A correlation between the timing of
biopsy after autologous chondrocyte implantation and the histological
appearance. The Journal of bone and joint surgery British volume. 2009 Sep
1;91(9):1172-7.
Brown WE, Potter HG, Marx RG et al. Magnetic resonance imaging
appearance of cartilage repair in the knee. Clin Orthop Relat Res. 2004
May(422):214-23.
Trattnig S, Domayer S, Welsch GW et al. MR imaging of cartilage and its
repair in the knee--a review. European radiology. 2009 Jul 1;19(7):1582-94.
Peterson L, Brittberg M, Kiviranta I et al. Autologous chondrocyte
transplantation. Biomechanics and long-term durability. Am J Sports Med.
2002 Jan-Feb;30(1):2-12.
Kon E, Delcogliano M, Filardo G et al. Second generation issues in cartilage
repair. Sports medicine and arthroscopy review. 2008 Dec 1;16(4):221-9.
Mandelbaum B, Browne JE, Fu F et al. Treatment outcomes of autologous
chondrocyte implantation for full-thickness articular cartilage defects of the
trochlea. Am J Sports Med. 2007 Jun;35(6):915-21.
Kon E, Gobbi A, Filardo G et al. Arthroscopic second-generation autologous
chondrocyte implantation compared with microfracture for chondral lesions
of the knee: prospective nonrandomized study at 5 years. Am J Sports Med.
2009 Jan;37(1):33-41.
Cole BJ. A randomized trial comparing autologous chondrocyte implantation
with microfracture. J Bone Joint Surg Am. 2008 May;90(5):1165; author reply
-6.
Bentley G, Biant LC, Carrington RW et al. A prospective, randomised
comparison of autologous chondrocyte implantation versus mosaicplasty for
osteochondral defects in the knee. J Bone Joint Surg Br. 2003 Mar;85(2):22330.
Horas U, Pelinkovic D, Herr G et al. Autologous chondrocyte implantation and
osteochondral cylinder transplantation in cartilage repair of the knee joint. A
Fo
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
International Journal of Clinical Practice
International Journal of Clinical Practice
Page 22 of 26
International Journal of Clinical Practice
60.
61.
62.
63.
67.
72.
ly
71.
On
70.
iew
69.
ev
68.
rR
66.
ee
65.
rP
64.
prospective, comparative trial. J Bone Joint Surg Am. 2003 Feb;85-A(2):18592.
Basad E. Treatment of chondral defects with MACI or microfracture. First
results of a comparative clinical study. Orthopädische Praxis. 2004;40:5.
Wasiak J, Clar C, Villanueva E. Autologous cartilage implantation for full
thickness articular cartilage defects of the knee. Cochrane database of
systematic reviews (Online). 2006 Jan 1;3:CD003323.
Saris DB, Vanlauwe J, Victor J et al. Characterized chondrocyte implantation
results in better structural repair when treating symptomatic cartilage
defects of the knee in a randomized controlled trial versus microfracture. Am
J Sports Med. 2008 Feb;36(2):235-46.
Van Assche D, Staes F, Van Caspel D et al. Autologous chondrocyte
implantation versus microfracture for knee cartilage injury: a prospective
randomized trial, with 2-year follow-up. Knee Surg Sports Traumatol
Arthrosc. 2009 Oct 10.
Magnussen RA, Dunn WR, Carey JL, Spindler KP. Treatment of focal articular
cartilage defects in the knee: a systematic review. Clin Orthop Relat Res. 2008
Apr;466(4):952-62.
Minas T. Chondrocyte implantation in the repair of chondral lesions of the
knee: economics and quality of life. Am J Orthop. 1998 Nov;27(11):739-44.
Jakobsen RB, Engebretsen L, Slauterbeck JR. An analysis of the quality of
cartilage repair studies. J Bone Joint Surg Am. 2005 Oct;87(10):2232-9.
Wood JJ, Malek MA, Frassica FJ et al. Autologous cultured chondrocytes:
adverse events reported to the United States Food and Drug Administration.
The Journal of bone and joint surgery American volume. 2006 Mar
1;88(3):503-7.
Behrens P, Bitter T, Kurz B, Russlies M. Matrix-associated autologous
chondrocyte transplantation/implantation (MACT/MACI)--5-year follow-up.
Knee. 2006 Jun;13(3):194-202.
Zeifang F, Oberle D, Nierhoff C et al. Autologous Chondrocyte Implantation
Using the Original Periosteum-Cover Technique Versus Matrix-Associated
Autologous Chondrocyte Implantation: A Randomized Clinical Trial. Am J
Sports Med. 2009 Dec 4.
Hettrich CM, Crawford D, Rodeo SA. Cartilage repair: third-generation cellbased technologies--basic science, surgical techniques, clinical outcomes.
Sports medicine and arthroscopy review. 2008 Dec 1;16(4):230-5.
Image available from:
http://tc.engr.wisc.edu/UER/uer01/author1/. Accessed 05 Jan 2010.
Lutzner J, Kasten P, Gunther KP, Kirschner S. Surgical options for patients with
osteoarthritis of the knee. Nat Rev Rheumatol. 2009 Jun;5(6):309-16.
Fo
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
International Journal of Clinical Practice
Page 23 of 26
w
ie
ev
rR
ee
rP
Fo
ly
On
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
International Journal of Clinical Practice
International Journal of Clinical Practice
International Journal of Clinical Practice
w
ie
ev
rR
ee
rP
Fo
ly
On
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Page 24 of 26
International Journal of Clinical Practice
Page 25 of 26
w
ie
ev
rR
ee
rP
Fo
ly
On
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
International Journal of Clinical Practice
International Journal of Clinical Practice
International Journal of Clinical Practice
w
ie
ev
rR
ee
rP
Fo
ly
On
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Page 26 of 26
International Journal of Clinical Practice